Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative
Giorgio L Colombo,1,2 Sergio Di Matteo,2 Chiara Martinotti,2 Steffen M Jugl,3 Praveen Gunda,4 Mariantonietta Naclerio,5 Giacomo M Bruno2 1Department of Drug Science, Pavia University, Pavia, Italy; 2S.A.V.E. S.r.l. Studi Analisi Valutazioni Economiche Health Economics & Outcomes Research - r...
Main Authors: | Colombo GL, Di Matteo S, Martinotti C, Jugl SM, Gunda P, Naclerio M, Bruno GM |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-08-01
|
Series: | ClinicoEconomics and Outcomes Research |
Subjects: | |
Online Access: | https://www.dovepress.com/budget-impact-model-of-secukinumab-for-the-treatment-of-moderate-to-se-peer-reviewed-article-CEOR |
Similar Items
-
Secukinumab for ankylosing spondylitis and psoriatic arthritis
by: Lubrano E, et al.
Published: (2016-10-01) -
Short-term Efficacy and Safety of Secukinumab in Pakistani Patients with Ankylosing Spondylitis and Psoriatic Arthritis
by: Sumera Ghani, et al.
Published: (2023-06-01) -
Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland
by: Purmonen T, et al.
Published: (2019-02-01) -
Successful Treatment of SAPHO Syndrome Complicated with Ankylosing Spondylitis by Secukinumab: A Case Report
by: Wei Tu, et al.
Published: (2023-03-01) -
Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data
by: Alice B. Gottlieb, et al.
Published: (2022-04-01)